STOCK TITAN
  1. Home
  2. News
  3. LIFE

Atyr Pharma Inc - LIFE STOCK NEWS

Welcome to our dedicated news page for Atyr Pharma (Ticker: LIFE), a resource for investors and traders seeking the latest updates and insights on Atyr Pharma.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Atyr Pharma's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Atyr Pharma's position in the market.

News
aTyr Pharma to Participate in April Investor Conferences
Rhea-AI Summary
aTyr Pharma, Inc. (Nasdaq: LIFE) will participate in two investor conferences in April 2024. The company focuses on developing innovative medicines from its tRNA synthetase platform. Their lead candidate, efzofitimod, targets interstitial lung disease.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.05%
Tags
conferences
-
News
aTyr Pharma Announces Fourth Quarter and Full Year 2023 Results and Provides Corporate Update
Rhea-AI Summary
aTyr Pharma, Inc. (Nasdaq: LIFE) announces fourth quarter and full year 2023 results. The company focuses on efzofitimod for ILD treatment, with Phase 3 EFZO-FIT™ study in pulmonary sarcoidosis ongoing. The company ended 2023 with $101.7 million in cash. Key highlights include an Individual Patient Expanded Access Program, Phase 2 EFZO-CONNECT™ study, and upcoming presentations at medical conferences.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
22.84%
Tags
earnings
-
News
aTyr Pharma to Webcast Conference Call Reporting Fourth Quarter and Full Year End 2023 Financial Results
Rhea-AI Summary
aTyr Pharma, Inc. (LIFE) to report Q4 and full year 2023 financial results on March 14, 2024. Conference call and webcast scheduled to discuss the results and provide a corporate update.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5%
Tags
conferences earnings
News
aTyr Pharma Announces Expanded Access Program (EAP) for EFZO-FIT™ Clinical Trial Participants
Rhea-AI Summary
aTyr Pharma, Inc. announces an Individual Patient EAP for efzofitimod in pulmonary sarcoidosis post Phase 3 EFZO-FIT™ study. The EAP provides access to patients completing the study, aiming to offer treatment outside the trial. Efzofitimod, a tRNA synthetase derived therapy, is being investigated in global Phase 3 and Phase 2 studies for ILD treatment. The EFZO-FIT™ study is a double-blind, placebo-controlled trial evaluating efzofitimod's efficacy and safety in pulmonary sarcoidosis.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.79%
Tags
clinical trial
-
News
aTyr Pharma Announces Howard University President Emeritus Dr. Wayne A. I. Frederick as Advisor
Rhea-AI Summary
aTyr Pharma appoints Dr. Frederick as an advisor to advise on corporate affairs and commercial strategy for efzofitimod in interstitial lung disease. Efzofitimod is a first-in-class biologic immunomodulator in clinical development for the treatment of ILD. Dr. Frederick's expertise in healthcare disparities and clinical background makes him a valuable addition to aTyr's team.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.41%
Tags
none
-
News
aTyr Pharma Presents Poster Demonstrating Preclinical Effects of Efzofitimod in Rheumatoid Arthritis and Rheumatoid Arthritis-Associated ILD at the ACR Convergence 2023
Rhea-AI Summary
aTyr Pharma, Inc. (Nasdaq: LIFE) announced positive preclinical data for efzofitimod, its lead therapeutic candidate, at the American College of Rheumatology Convergence 2023. The data demonstrated efzofitimod's immune regulatory function in treating rheumatoid arthritis (RA) and RA-associated interstitial lung disease (RA-ILD), indicating its potential broader application in treating inflammatory diseases beyond respiratory conditions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.45%
Tags
none
News
aTyr Pharma Announces Third Quarter 2023 Results and Provides Corporate Update
Rhea-AI Summary
aTyr Pharma, Inc. (Nasdaq: LIFE) announced the completion of enrollment in the Phase 3 EFZO-FIT™ study for efzofitimod in pulmonary sarcoidosis, with positive DSMB review. The Phase 2 EFZO-CONNECT™ study for SSc-ILD also initiated patient dosing. Ended Q3 2023 with $105.6 million in cash, cash equivalents and investments.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.61%
Tags
earnings
-
News
aTyr Pharma to Present at November Investor Conferences
Rhea-AI Summary
aTyr Pharma, Inc. (Nasdaq: LIFE) will present at two investor conferences in November 2023. The first is the Jefferies London Healthcare Conference on November 15 in London, UK, and the second is the Piper Sandler 35th Annual Healthcare Conference on November 30 in New York, NY. The company's management will also be available for one-on-one meetings with investors. Webcasts of each event will be available on the company's website, and replays will be accessible for at least 90 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.6%
Tags
conferences
-
News
aTyr Pharma Announces Dosing of First Patient in Phase 2 EFZO-CONNECT™ Study of Efzofitimod in Patients with SSc-ILD
Rhea-AI Summary
aTyr Pharma has dosed the first patient in its Phase 2 EFZO-CONNECT study, which will evaluate the efficacy of efzofitimod in patients with systemic sclerosis-related interstitial lung disease. Efzofitimod is a biologic immunomodulator that has been granted orphan drug and Fast Track designations by the FDA. The study aims to enroll 25 patients at multiple centers in the US.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
clinical trial
News
aTyr Pharma Presents Efzofitimod Data Demonstrating Statistically Significant Improvements in Time to Relapse, FVC and Patient Reported Outcomes
Rhea-AI Summary
Post-hoc analysis shows promising results for efzofitimod in pulmonary sarcoidosis treatment
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Stock LIFE logo
Atyr Pharma Inc

Nasdaq:LIFE

LIFE Rankings

#4179 Ranked by Market Cap
#4700 Ranked by Stock Gains
N/A Ranked by Dividends

LIFE Stock Data

118.22M
60.12M
2.62%
61.73%
0.64%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
US
San Diego

About LIFE

atyr pharma (nasdaq: life) is engaged in the discovery and clinical development of innovative medicines for patients suffering from severe rare diseases using its knowledge of physiocrine biology, a newly discovered set of physiological modulators. the company's lead candidate, resolaris™, is a first-in-class intravenous protein therapeutic for the treatment of rare myopathies with an immune component. resolaris is currently in a phase 1b/2 clinical trial in adult patients with facioscapulohumeral muscular dystrophy (fshd); a phase 1b/2 trial in adult patients with limb girdle muscular dystrophy (lgmd) 2b or fshd; and a phase 1b/2 trial in patients with an early onset form of fshd. to protect this pipeline, atyr built an intellectual property estate comprising 70 issued or allowed patents and over 240 pending patent applications that are solely owned or exclusively licensed by atyr. atyr's key programs are currently focused on severe, rare diseases characterized by immune dysregulation